Home > Science > Autism Speaks Participates in FasterCures “Crossing the Valley of Death” Forum

Autism Speaks Participates in FasterCures “Crossing the Valley of Death” Forum

As more and more is learned about the biology of autism, the development of novel medicines to treat its core symptoms is no longer just a hope.  Therefore Autism Speaks was pleased to be invited to participate in the 5th annual FasterCures-Esquire Leadership Forum, devoted this year to the topic of translational research, that is, how to translate knowledge gained from basic research into products that can provide real healthcare benefits for patients.

FasterCures, a Washington D.C. think tank focused on accelerating medical solutions, is based on the founding principle that saving time saves lives.  Since 2005 they have brought together a cross-disciplinary group of innovative thinkers to explore novel approaches that hold the potential to accelerate the search for new treatments and cures for diseases.  With representatives of biotechnology, pharmaceutical and patient advocacy organizations in attendance, the theme for this year’s small workshop was to determine action items to achieve innovation in drug development.   Attendees agreed that in order for this to happen as fast as possible, there needs to be better integration between all stakeholders – patients, financiers, academic researchers and for-profit companies alike.  The meeting participants called for the identification of new business models and research paradigms to achieve this integration.

Full of buzz words such as “open innovation,” “collaboration,” and “entrepreneurship,” the discussions focused on identifying the organizational and cultural barriers that influence the interface between traditional academic research and industry-related drug development.   This interface has long been called the “Valley of Death” because of the enormous difficulty in translating research discoveries into viable medical solutions.   While the government has begun several initiatives to push biomedical research forward across the Valley of Death, for-profit organizations such as pharmaceutical and biotechnology companies are beginning to unite to address the challenges that make it inefficient and, at times, impossible, to carry forward such risky and costly research on their own.  Some of the challenges identified at the meeting include the many knowledge gaps that remain in our basic understanding of human biology, the lack of financial incentives to work in some disease areas, and the constraints created by business policies that are meant to provide competitive advantages but instead often hinder progress.

The short meeting highlighted lessons learned from other industries and several new models of collaboration.   At its conclusion the participants agreed that streamlining the drug development process will involve not just procedural improvements but much more partnering than has ever been attempted before, including between individual pharmaceutical companies and between pharmaceutical companies and academia.  This opens a role for non-profit advocacy organizations such as Autism Speaks in bringing together the many diverse players, each with their own motivations and incentives.   Towards this end, Autism Speaks has recently formed a Translational Research Initiative that aims to enhance communication between academic scientists and industry representatives and nurture our renewed hopes for successful translational research in autism and new healthcare solutions.

Read more about translational research from our Chief Science Officer, Dr. Geri Dawson.

  1. Lew
    September 24, 2010 at 1:13 am

    College Living for Students with Learning Disabilities, Executive functioning Deficits, Autism Spectrum Disorders (including Autism, Aspergers, and PDD-NOS)

    For students with special needs, life after high school is full of possibilities, including college.

    Finding the right college program for students with autism spectrum disorders, Asperger’s, nonverbal learning disorder, ADD/ADHD and other learning disabilities is vital for a college student’s transition into independent adulthood. The right program should provide support for each student’s unique needs and goals.

    With the help of New Directions, young adults with learning disabilities are experiencing independence for the first time in their lives. Some of our clients pursue collegiate endeavors and some pursue vocational training/tracks. New Directions helps students attend universities, community colleges, and technical and vocational schools.

    For more information, go to http://www.newdirectionsfya.com/ or call 954-571-5102 to contact Dr. Drew Rubin, Ph.D.

  2. Katie Wright
    September 24, 2010 at 2:59 pm

    We have got to do more than streamline drug development.Getting drug approvals takes many years.

    Let’s start by listening to families and ask them what they need as far as translational help. We can begin by prioritizing research addressing ASD quality of life issues and medical needs right now.

    Talk to cutting edge ASD clinicians and ask and their needs and what they see as gaps right now on the way to a real cure.

    Who is on the Translational Research Committee?

    There should to be many non AS employees who are parents of a diverse group of affected ASD kids in order for this to work and not be another staid talkathon think tank.

    Family members are the ones that know the most about the for translational medicine right now.

    This a good effort by AS but once again why were the ASD public not invited to attend or participate?
    Part of the reason we have spent so much money and have made so little progress on biomedical interventions is that academics are not living autism and neither are many doctors. Their priorities have not been our priorities.
    Let’s cure gut disease, let’s cure sensory disorders, let’s cure SIBs, let’s develop programs to give IPads to nonverbal kids and “cure” their isolation and or their inability to communicate. Let’s partner w/ Apple.

    This is so much bigger than drug development.

  1. No trackbacks yet.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Follow

Get every new post delivered to your Inbox.

Join 1,049 other followers

%d bloggers like this: